1. Home
  2. BHVN vs GENB Comparison

BHVN vs GENB Comparison

Compare BHVN & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biohaven Ltd.

BHVN

Biohaven Ltd.

HOLD

Current Price

$14.53

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$15.12

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BHVN
GENB
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2022
2026

Fundamental Metrics

Financial Performance
Metric
BHVN
GENB
Price
$14.53
$15.12
Analyst Decision
Buy
Strong Buy
Analyst Count
14
6
Target Price
$29.08
$23.20
AVG Volume (30 Days)
1.8M
479.9K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
26.08
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.48
$11.00
52 Week High
$18.57
$18.18

Technical Indicators

Market Signals
Indicator
BHVN
GENB
Relative Strength Index (RSI) 52.79 55.37
Support Level $13.84 $11.82
Resistance Level $15.79 $16.75
Average True Range (ATR) 0.65 0.80
MACD 0.04 0.18
Stochastic Oscillator 75.92 77.59

Price Performance

Historical Comparison
BHVN
GENB

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: